Breast cancers driven by HER2 homodimers have been shown to be more sensitive to Tz 27 so crosslinking may offer a therapeutic advantage by enabling targeting of tumours driven by HER2:HER3 heterodimers. This evidence concerns the gene ERBB2 and breast carcinoma.